```html

Vaccine‑Preventable Diseases (e.g., Varicella)

Overview

Vaccine‑preventable diseases are infections that can be avoided—or greatly reduced in severity—through the use of safe, effective vaccines. One of the most common examples is varicella, better known as chickenpox. While the varicella‑zoster virus (VZV) also causes shingles later in life, the acute infection in children and adults is what we refer to as varicella.

• Who it affects: Anyone who has not been vaccinated or previously infected. In the United States, >90 % of children receive at least one dose of the varicella vaccine, but cases still occur in unvaccinated or partially vaccinated individuals, especially in communities with low vaccination rates.
• Global prevalence: According to the World Health Organization (WHO), before universal vaccination, varicella caused ~4.2 million severe cases and ~4,200 deaths worldwide each year. In the post‑vaccine era (2020‑2023), high‑income countries report a 70–90 % decline in hospitalizations for varicella.

Other vaccine‑preventable diseases that share similar transmission routes and public‑health challenges include measles, rubella, mumps, and pertussis. This guide focuses on varicella as a representative condition, but many of the prevention and management principles apply broadly.

Symptoms

The clinical picture of varicella can range from a mild, self‑limited rash to a severe systemic illness. Symptoms usually appear 10‑21 days after exposure (incubation period).

Early (Prodromal) Symptoms

• Fever: Often low‑grade (38‑39 °C) but can rise above 40 °C in severe cases.
• Headache & malaise: General feeling of being unwell.
• Loss of appetite and mild abdominal discomfort.

Cutaneous Manifestations

• Maculopapular rash: Small pink spots that develop into fluid‑filled vesicles.
• Vesicles: 1–5 mm blisters that rupture, forming crusted lesions.
• Distribution: Begins on the face and trunk, then spreads to the scalp, limbs, and mucous membranes. New lesions appear for 2‑4 days, resulting in lesions of different ages (“crops”).

Systemic Symptoms (may accompany rash)

• Fatigue, irritability (especially in children)
• Muscle aches (myalgia)
• Upper respiratory symptoms (runny nose, mild cough)

Complicated Presentations

• High‑grade fever > 40 °C lasting > 3 days
• Severe headache or neck stiffness (possible meningitis)
• Persistent vomiting or abdominal pain (possible intussusception)
• Worsening rash with necrotic or hemorrhagic lesions

Causes and Risk Factors

What Causes Varicella?

Varicella is caused by primary infection with the varicella‑zoster virus (VZV), a member of the herpesvirus family. The virus spreads mainly through:

• Respiratory droplets: Coughing or sneezing.
• Direct contact: Touching vesicular fluid from skin lesions.
• Aerosolized particles: Airborne spread can occur in crowded indoor settings.

Risk Factors for Infection

• Unvaccinated status: No prior VZV immunization or natural infection.
• Age: Most cases occur in children < 12 years; however, adults who are unvaccinated are at higher risk for severe disease.
• Immunocompromised state: HIV/AIDS, chemotherapy, organ transplantation, or long‑term corticosteroid use.
• Pregnancy: Increases risk of severe maternal disease and congenital varicella syndrome.
• Living in crowded settings: Schools, daycare centers, prisons, and refugee camps facilitate transmission.

Why Vaccination Works

The live attenuated varicella vaccine (Varivax™) stimulates the immune system to produce protective antibodies without causing full‑blown disease. Two doses provide > 95 % efficacy against any varicella infection and > 99 % protection against severe disease.

Diagnosis

Diagnosis is largely clinical, but laboratory confirmation may be needed when the presentation is atypical or when the patient is immunocompromised.

Clinical Assessment

• History of exposure, vaccination status, and symptom timeline.
• Physical exam documenting the characteristic “crops” of lesions.

Laboratory Tests

• Polymerase Chain Reaction (PCR): Detects VZV DNA from lesion swabs, blood, or cerebrospinal fluid (CSF). PCR is the most sensitive test.
• Direct Fluorescent Antibody (DFA): Rapid test on lesion scrapings; useful in outpatient settings.
• Serology (IgM/IgG): IgM indicates recent infection; IgG shows past exposure or vaccine‑induced immunity.
• Complete Blood Count (CBC): May show lymphocytosis in early infection.

Imaging (when complications suspected)

• Chest X‑ray for pneumonia.
• CT/MRI of brain if neurological involvement (encephalitis, cerebellitis) is suspected.

Treatment Options

Most healthy children recover with supportive care alone. Treatment strategies differ based on severity, age, and immune status.

Supportive Care (Mild to Moderate Cases)

• Fever control: Acetaminophen (paracetamol) 10‑15 mg/kg every 4–6 h; avoid aspirin due to Reye’s syndrome risk.
• Hydration: Encourage oral fluids; treat dehydration if present.
• Skin care: Keep nails trimmed, use mild soap, apply calamine lotion or cool compresses to relieve itching.
• Antihistamines: Oral diphenhydramine for severe itching (consult provider for dosing).

Antiviral Therapy

Antivirals are recommended for:

• Adults, especially > 20 years old
• Immunocompromised patients
• Pregnant women (after risk‑benefit discussion)
• Severe cutaneous disease (e.g., > 100 lesions)

First‑line agent: Acyclovir 800 mg orally five times daily for 5 days (or 10 mg/kg IV q8h for hospitalized patients). Alternatives include valacyclovir and famciclovir, which have more convenient dosing.

Hospital‑Based Interventions

• IV acyclovir for severe or disseminated disease.
• Broad‑spectrum antibiotics if secondary bacterial infection of skin lesions is suspected.
• Respiratory support for varicella pneumonia (oxygen, mechanical ventilation).
• Intravenous immunoglobulin (IVIG) for selected immunodeficient patients.

Post‑Exposure Prophylaxis (PEP)

• Vaccination: One dose of varicella vaccine within 3–5 days of exposure for susceptible individuals (except pregnant women and severely immunocompromised).
• Varicella‑Zoster Immune Globulin (VZIG): Given intramuscularly within 96 h of exposure for high‑risk groups (e.g., newborns, pregnant women, immunocompromised).

Living with Vaccine‑Preventable Diseases (e.g., Varicella)

While the best strategy is prevention, people who contract varicella or have a history of the disease need practical guidance to minimize discomfort and reduce transmission.

Daily Management Tips

• Isolation: Stay home from school, work, or daycare until all lesions have crusted (usually 5‑7 days after rash onset).
• Hygiene: Wash hands frequently, use separate towels, and disinfect surfaces with bleach‑based cleaners.
• Skin care: Apply calamine lotion or oatmeal baths to soothe itching.
• Nutrition: Eat balanced meals rich in vitamin C and zinc to support immune function.
• Rest: Adequate sleep (8–10 h for children, 7–9 h for adults) aids viral clearance.
• Monitor for complications: Keep a daily log of fever, rash progression, and any new symptoms (e.g., severe headache, vomiting).

Psychosocial Support

Children may feel self‑conscious about visible lesions. Reassure them that the rash is temporary and that peers will understand if they explain they have a “chickenpox” infection. Provide age‑appropriate information to reduce anxiety.

Prevention

Vaccination remains the single most effective preventive measure.

Vaccination Schedule (U.S. CDC Recommendations)

• First dose: 12‑15 months of age.
• Second dose: 4‑6 years of age (or at least 3 months after the first dose).
• Catch‑up: Unvaccinated children 7‑12 years receive two doses 3 months apart; adolescents 13‑17 years receive one dose if previously unvaccinated.

Additional Preventive Strategies

• Hand hygiene: Wash hands with soap for at least 20 seconds after coughing, sneezing, or touching lesions.
• Respiratory etiquette: Cover mouth/nose with a tissue or elbow when coughing/sneezing.
• Environmental cleaning: Daily disinfection of high‑touch surfaces in homes and schools.
• Travel precautions: Verify vaccination status before international travel, especially to regions with low vaccine coverage.
• Pregnancy counseling: Women of child‑bearing age should confirm immunity (serologic testing) and receive vaccination before conception if non‑immune.

Complications

Although most cases are mild, complications can be serious, especially in adults and immunocompromised hosts.

• Bacterial superinfection: Impetigo, cellulitis, or invasive Staphylococcus aureus infections of skin lesions.
• Neurologic: Encephalitis (0.1 % of cases), cerebellar ataxia, meningitis.
• Respiratory: Varicella pneumonia (more common in adults; up to 15 % mortality without treatment).
• Hepatic & renal: Transient hepatitis or nephritis.
• Hemorrhagic varicella: Rare but life‑threatening, characterized by extensive bruising and bleeding from lesions.
• Congenital varicella syndrome: Fetal infection when a pregnant woman contracts varicella in the first or early second trimester, leading to limb hypoplasia, eye defects, and neurological impairment.

When to Seek Emergency Care

References

• Mayo Clinic. “Chickenpox (Varicella).” mayoclinic.org. Accessed May 2026.
• Centers for Disease Control and Prevention. “Varicella (Chickenpox) Vaccination.” cdc.gov. Updated 2024.
• World Health Organization. “Varicella‑zoster virus infections.” who.int. 2023.
• National Institutes of Health. “Varicella‑Zoster Virus.” NIH Fact Sheet, 2022.
• Cleveland Clinic. “Chickenpox (Varicella) – Symptoms, Treatment, and Prevention.” clevelandclinic.org. 2024.
• American Academy of Pediatrics. “Immunization of Infants, Children, and Adolescents (Red Book).” 2024 edition.

```